Table 1.
Demographic and clinical features of patients with different stages of fibrosis.
Figure 1.
Measurement of liver stiffness by transient elastography and serological detection of ELF score in patients with chronic liver diseases and minimal (F0-1), moderate (F2-4) or high (F5-6) stages of fibrosis.
Data are presented as box plots including medians and 25th and 75th percentiles. Both non-invasive methods can significantly discriminate between the different fibrosis stages. Transient elastography (A) allowed a better discrimination between minimal and moderate fibrosis stages (p<0.01) compared to ELF score (B; p<0.05). *P<0.05; **P<0.01; ***P<0.001. ELF, enhanced liver fibrosis.
Table 2.
Correlation of ELF score or liver stiffness measured by transient elastograpgy with histological fibrosis.
Figure 2.
Prediction of relevant or advanced fibrosis stages by transient elastography and ELF score.
The cut-off values of transient elastography (A, C) and ELF score (B, D) to predict fibrosis stages ≥F2 (A, B) or ≥F5 (C, D) with best compromise sensitivity/specificity were determined by ROC plot analysis. AUC, area under the curve; ELF, enhanced liver fibrosis; ROC, receiver operating characteristics.
Figure 3.
Regression analyses correlating liver stiffness measured by transient elastography or the ELF score with AST or ALT levels.
A significant correlation (at 0.01/two tailed) was observed between liver stiffness (A) and AST or ALT levels as well as between ELF score (B) and AST or ALT levels. ALT, alanine aminotransferase; AST, aspartate aminotransferase; ELF, enhanced liver fibrosis.
Table 3.
Correlation of ELF score or liver stiffness measured by transient elastography with histological disease activity (ISHAK A-D), steatosis and aminotransferase levels.